FindTrial
Sign In

Estradiol/norethindrone acetate placebo

DRUG4 trials

Sponsors

Myovant Sciences GmbH

Conditions

Endometriosis Related PainHeavy Menstrual BleedingUterine Fibroid

Phase 3

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
CompletedNCT03049735
Myovant Sciences GmbHHeavy Menstrual Bleeding, Uterine Fibroid
Start: 2017-04-26End: 2020-08-24Updated: 2022-04-19
LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
CompletedNCT03103087
Myovant Sciences GmbHHeavy Menstrual Bleeding, Uterine Fibroid
Start: 2017-06-14End: 2020-09-16Updated: 2022-04-20
SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
CompletedNCT03204331
Myovant Sciences GmbHEndometriosis Related Pain
Start: 2017-11-01End: 2021-05-31Updated: 2021-06-28
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
CompletedNCT03204318
Myovant Sciences GmbHEndometriosis Related Pain
Start: 2017-12-07End: 2021-04-08Updated: 2021-06-28

Related Papers

Efficacy and safety of relugolix combination therapy in women with uterine fibroids and adenomyosis: subgroup analysis of LIBERTY 1 and LIBERTY 2
Fertility and Sterility2025-05-022 citations
A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy
Pain Management2024-09-01
P-308 Relugolix combination therapy vs relugolix monotherapy with transition to relugolix combination therapy for the treatment of endometriosis-associated pain: implications for cumulative benefit/risk profile
Human Reproduction2024-07-01
Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study
Human Reproduction2024-01-1834 citations
A Plain Language Summary to Learn About Relugolix Combination Therapy for the Treatment of Pain Associated with Endometriosis
Pain Management2023-11-013 citations
Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
2023-10-187 citations
A plain language summary of the long-term relugolix combination therapy study for uterine fibroids
Journal of Comparative Effectiveness Research2023-07-21
Endometriosis Symptoms and Their Impacts on the Daily Lives of US Women: Results from an Interview Study.
2023-06-0110 citations
O-032 Effect of relugolix combination therapy in women with endometriosis-associated pain who received prior first-line hormonal treatment: SPIRIT 1 and 2
Human Reproduction2023-06-01
O-191 Effects of relugolix combination therapy (Relugolix-CT) on uterine fibroid (UF) and uterine volume through 52 weeks: post hoc analysis of the LIBERTY Long-Term Extension study
Human Reproduction2023-06-01
A Plain Language Summary of the Safety of Relugolix Combination Therapy and Improvement in Symptoms in Women with Uterine Fibroids from the LIBERTY 1 and LIBERTY 2 Studies
Pain Management2023-04-011 citations
Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
Obstetrics and Gynecology2022-11-0237 citations
Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
2022-06-0195 citations
Relugolix Combination Therapy for Uterine Leiomyoma–Associated Pain in the LIBERTY Randomized Trials
Obstetrics and Gynecology2022-05-0221 citations
The Burden of Uterine Fibroids from the Perspective of US Women Participating in Open-Ended Interviews.
2022-03-048 citations
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
BMC Women s Health2021-10-2829 citations
O-131 The effect of time since surgical diagnosis of endometriosis on treatment outcomes with relugolix combination therapy in women with endometriosis-associated pain: SPIRIT program
Human Reproduction2021-07-01
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
BMC Women s Health2021-06-2127 citations
Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy
New England Journal of Medicine2021-02-17182 citations